# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Bernstein analyst William Pickering upgrades Ionis Pharmaceuticals (NASDAQ:IONS) from Underperform to Market Perform.
Needham analyst Joseph Stringer reiterates Ionis Pharmaceuticals (NASDAQ:IONS) with a Buy and maintains $60 price target.
Discover the results of Ionis Pharmaceuticals' Phase 3 studies on donidalorsen for hereditary angioedema. FDA application s...
The European Commission has granted exceptional marketing authorization for Biogen's Qalsody (tofersen), the first EU-appro...
WAINUA was approved by the FDA in December 2023 for the treatment of the polyneuropathy of hereditary transthyretin-mediated am...
Ionis Pharmaceuticals and Biogen have halted development of BIIB105 for ALS after Phase 1/2 study results showed no impact on k...